Last reviewed · How we verify
NCT04675138
Development of a Clinical Decision Support System With Artificial Intelligence for Cancer Care
trial testing No intervention will be provided to the subject in Gastric Cancer in 1,000 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | National University Hospital, Singapore |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 20 August 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 9 locations across Japan, Sweden, United Kingdom, Germany, South Korea, Singapore |
Drugs / interventions tested
- No intervention will be provided to the subject
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Esophagogastric Junction Cancer — all drugs for Esophagogastric Junction Cancer →
Sponsor
National University Hospital, Singapore
Who can join
21 and older, any sex, with Gastric Cancer or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Decision Support Systems (CDSSs) to augment clinical care and decision making. These are platforms which aim to improve healthcare delivery by enhancing medical decisions with targeted clinical knowledge, patient information, and other health information. In view of the benefit of developing a CDSS, we sought to develop an alternative CDSS for oncologic therapy selection through a partnership with Ping An Technology (Shenzhen, China), beginning with gastric and oesophagal cancer. This would be done in a piecemeal fashion, with the prototype platform utilizing only international guidelines and high-quality published evidence from journals to arrive at case-specific treatment recommendations. This platform would then be evaluated by comparing its recommendations with that from the multidisciplinary tumour boards of several tertiary care institutions to determine the concordance rate.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Artificial intelligence in gastric cancer: applications and challenges.
Cao R, Tang L, Fang M, Zhong L, et al · · 2022 · cited 25× · PMID 36457374 · DOI 10.1093/gastro/goac064 -
Current Role of Artificial Intelligence in the Management of Esophageal Cancer.
Mela E, Tsapralis D, Papaconstantinou D, Sakarellos P, et al · · 2025 · cited 3× · PMID 40142652 · DOI 10.3390/jcm14061845 -
Current Role of Artificial Intelligence in the Management of Gastric Cancer.
Liatsou E, Driva TS, Vergadis C, Sakellariou S, et al · · 2025 · PMID 41462951 · DOI 10.3390/biomedicines13122939
Verify or expand the search:
- PubMed search for NCT04675138
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other National University Hospital, Singapore trials
Trials by the same sponsor.
- NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
- NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04675138 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
- Last refreshed: 10 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04675138.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing